The University of Virginia is conducting a clinical research study for adults ages 18 to 79, who have Multiple Myeloma. This research study is evaluating whether receiving the study medication with lenalidomide improves disease response in Multiple Myeloma.
If you join this study you will be randomly assigned to either receive lenalidomide alone or both lenalidomide and the study medication along with medications to take before and after the study medication injection.

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with Merkel Cell Carcinoma for a research study. The purpose of the study is to compare the usual approach of post-surgery observation with or without radiation to using pembrolizumab with or without radiation after surgery. This drug, pembrolizumab, is already approved by the FDA for use in other cancers.

This study has 2 study groups:

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over, who have advanced, recurrent or metastatic endometrioid endometrial cancer. The purpose of this study is to find out if the combination of 2 immunotherapy drugs (Abemaciclib and Letrozole) is better or worse than usual approach for endometrial cancers.

Participation includes taking the study medication and attend clinic visits. Each treatment cycle is 4 weeks. The length of participation is dependent on how well you respond to the treatment.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have an advanced type of breast cancer known as Hormone Receptor positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2-) negative advanced or metastatic breast cancer (MBC) or small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC) or advanced platinum resistant epithelial ovarian cancer (EOC)/fallopian tube cancer/primary peritoneal cancer (PPC).

The University of Virginia Cancer Center seeks participants for a Research Database that collects data on the outcomes of stem cell transplants and other cellular treatments. The Research Database is a comprehensive source of data that can be used to study hematopoietic cell transplantation (HCT) and cellular therapy (CT). The sponsor of this study, the Center for International Blood and Marrow Transplant Research (CIBMTR) uses the data in order to find ways to make bone marrow and stem cell transplants work better for both recipients and donors.

The University of Virginia Comprehensive Cancer Center seeks women ages 18 and over with ovarian cancer to participate in a research study. The purpose of the study is to evaluate an investigational drug called ZN-c3 when given combination with niraparib at different dose levels, and identify which dose of ZN-c3 in combination with niraparib is the best dose that subjects can receive while trying to minimize severe symptoms, as well as looking at how your ovarian cancer responds to ZN-c3 in combination with niraparib.

The Department of Kinesiology seeks adults ages 18-44 with chronic ankle instability for a research study. The purpose of the study is to examine the effects of rehabilitation on short and long-term outcomes for people with chronic ankle instability

You may be eligible for this study if: you have not sustained an ankle sprain in the last four weeks, have not been diagnosed with any kind of neurological, vestibular, respiratory, or heart disorders, and are not pregnant.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have metastatic or locally recurrent inoperable triple-negative breast cancer.

The Neurology Department seeks adults ages 50 to 85 with Mild to Moderate Dementia with Lewy Bodies for a research study. The purpose of the study is to test the safety, tolerability, and effectiveness of an investigational medicine.

You may be eligible for this study if You:
-Have a diagnosis of Mild to Moderate Dementia with Lewy Bodies
-Have a study partner who agrees to participate
-Are in good general health with stable medications

The University of Virginia is conducting a clinical research study for adults ages 18 and over with stage I non-small lung cancer that has been completely removed by surgery. The purpose of the study is to find out if giving a drug called pembrolizumab after lung cancer surgery does a better job at keeping the cancer from coming back than surgery alone. The usual approach for patients who are not in a study is to be followed closely by their doctor to watch in case the cancer returns.